Favipiravir induces gout and is ineffective against COVID-19

The Thai Food and Drug Administration has cleared Favipiravir, Molnupiravir, Remdesivir, and Paxlovid for treatment on Covid virus patients. Dr. Manoon Leechawengongs of Vichaiyut Hospital in Thailand said on Facebook that Thailand must stop administering the ineffective medicine.


Thailand should move from Favipiravir to Molnupiravir, which is cheaper. Our neighbors went from Favipiravir to Molnupiravir or Paxlovid. [Government Pharmaceutical Organization] will no longer manufacture, import, or distribute favipiravir.


Thai respiratory doctor said antiviral medication raises gout risk due to higher uric acid levels. This 11-month experiment between November 2020 and October 2019 showed minimal to no benefit against coronavirus. Despite being well tolerated by infected individuals, Favipiravir did not reduce viral shedding, delay or prevent the progression to a severe infection, or shorten the time to sustained clinical recovery. Favipiravir increased uric acid by 19.9% compared to placebo. Favipiravir’s ineffectiveness against Covid-19 infections is bad news. Gout may ensue. In the trial, 599 Covid patients and 588 placebo patients with a comparable infection were compared. US, Brazil, and Mexico participants. “Favipiravir in Early Mild-to-Moderate Covid-19: A Randomized Control Trial” was published in August.